Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

CDE Granted LM-108 Breakthrough Therapy Designation for 2L CCR8-Positive G/GEJ Adenocarcinomas

  • 2025-06-26

  • Share:

SHANGHAI, June 26th, 2025 – LaNova Medicines Ltd. announced CDE has granted LM-108 (anti-CCR8 mAb) Breakthrough Therapy Designation. This designation is for the treatment of patients with CCR8-positive gastric or gastroesophageal junction adenocarcinoma who have disease progression following first-line standard of care treatment.